title: Reducing blood losses and transfusion requirements in craniosynostosis surgery:  an endless quest?
authors.forename: Estelle
authors.initials: E
authors.lastname: Vergnaud
authors.forename: Antonio
authors.initials: A
authors.lastname: Vecchione
authors.forename: Stéphane
authors.initials: S
authors.lastname: Blanot
authors.forename: Federicco
authors.initials: F
authors.lastname: di Rocco
authors.forename: Eric
authors.initials: E
authors.lastname: Arnaud
authors.forename: Dominique
authors.initials: D
authors.lastname: Renier
authors.forename: Philippe
authors.initials: P
authors.lastname: Meyer
mesh_terms: D000933:Antifibrinolytic Agents / Q000627:therapeutic use*; D016063:Blood Loss, Surgical / Q000517:prevention & control*; D001803:Blood Transfusion / Q000706:statistics & numerical data*; D003398:Craniosynostoses / Q000601:surgery*; D017558:Elective Surgical Procedures / Q000379:methods*; D005260:Female; D006801:Humans; D008297:Male; D014148:Tranexamic Acid / Q000627:therapeutic use*
chemical_list: D000933:Antifibrinolytic Agents; D014148:Tranexamic Acid